MedTrace Logo

Kinetics of B Cell Response in Infants Menjugate Vaccination

NCT00310700 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2014-09-19

No results posted yet for this study

Summary

Kinetics of B cell response in infants Menjugate vaccination

Conditions

  • Prevention of Meningococcal Infection

Interventions

BIOLOGICAL

Meningococcal C conjugate vaccine

Sponsors & Collaborators

  • Novartis Vaccines

    collaborator INDUSTRY

  • Novartis

    lead INDUSTRY

Principal Investigators

  • Novartis Vaccines - Information Services · Novartis Vaccines & Diagnostics

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Weeks
Max Age
11 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2005-11-30
Completion
2005-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00310700 on ClinicalTrials.gov